

30**OFFICIAL**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ozaki et al.

Serial No.: 09/214,881

Filed: June 7, 1999

For: DIAGNOSTIC DRUGS FOR AUTO
IMMUNE DISEASE§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1644

Examiner: Patrick Nolan

Att'y Docket: 13240.0004.NPUS00

Client Docket: F5-01F03832/
KA016-1 US RCEREQUEST FOR CONTINUED EXAMINATION (RCE)Commissioner for Patents
Washington, D.C. 20231CERTIFICATE OF TRANSMISSION
37 C.F.R. 1.8I hereby certify that this correspondence is being facsimile transmitted to
the U.S. Patent and Trademark Office to (703) 746-5303 on the date
below:27 SEP 02
Date
Signature

Sir:

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the
above identified application.

1. Submission required under 37 C.F.R. § 1.114

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116
previously filed on .
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief
previously filed on .
- iii. ☐ Other
- b. ☒ Enclosed
- i. ☒ Amendment/reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)

H: 500606(@Q9Q011.DOC)

10/01/2002 KDDNNING 09214881 012508 740.00 CH
01 FC:179

Handwritten initials and date: 29/10/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ozaki et al.

Serial No.: 09/214,881

Filed: June 7, 1999

For: DIAGNOSTIC DRUGS FOR AUTO
IMMUNE DISEASE§
§
§
§
§
§
§
§
§

Group Art Unit: 1644

Examiner: Patrick Nolan

Att'y Docket: 13240.0004.NPUS00

Client Docket: F5-01F03832/
KA016-1 US RCEPRELIMINARY AMENDMENTCommissioner for Patents
Washington, D.C. 20231CERTIFICATE OF TRANSMISSION
37 C.F.R. 1.8I hereby certify that this correspondence is being facsimile transmitted to
the U.S. Patent and Trademark Office to (703) 746-5303 on the date
below:27 SEP 02
Date
Signature

Sir:

Please amend this application as follows:

IN THE CLAIMS:

Please enter the following rewritten claim. A marked up version of the rewritten claim,
and a clean version of all pending claims are attached at the end of this document.

- Sub H1 / 6. (Three times amended) The kit of claim 4, wherein:
the polypeptide having an amino acid sequence homology of 90% or more with SEQ ID
NO:1 is selected from human, bovine, porcine, or rat HMG-1; and
the polypeptide having an amino acid sequence homology of 80% or more with SEQ ID
NO:2 is selected from human, bovine, porcine, chicken, mouse, or rat HMG-2.